RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+46.61%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.86B
AUM Growth
+$7.86B
(+23%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
3.56%
Top 10 Holdings %
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$163M |
| 2 |
Dyne Therapeutics
DYN
|
$141M |
| 3 |
Evolent Health
EVH
|
$105M |
| 4 |
LENZ
LENZ Therapeutics
LENZ
|
$93.3M |
| 5 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$71M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$704M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$164M |
| 3 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$94M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$93.6M |
| 5 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$73.2M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $1.53B | 19.44% | 10,108,400 +1,000 | +0% | +$151K |
|
2
Vaxcyte
PCVX
$4B
| $560M | 7.13% | 8,203,754 +312,500 | +4% | +$21.3M |
|
3
Legend Biotech
LEGN
$6.41B
| $385M | 4.9% | 6,861,097 +596,390 | +10% | +$33.5M |
|
4
Janux Therapeutics
JANX
$1.37B
| $345M | 4.39% | 9,165,652 | – | – |
|
|
JBIO
5
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $244M | 3.11% | 8,263,982 | – | – |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $231M | 2.94% | 5,330,412 | – | – |
|
|
7
Evolent Health
EVH
$1.12B
| $188M | 2.39% | 5,736,132 +3,187,000 | +125% | +$105M |
|
8
NewAmsterdam Pharma
NAMS
$2.71B
| $186M | 2.37% | 7,864,000 | – | – |
|
9
RxSight
RXST
$370M
| $178M | 2.26% | 3,442,825 +38,540 | +1% | +$1.99M |
|
10
Tyra Biosciences
TYRA
$675M
| $171M | 2.17% | 10,416,609 +3,180,155 | +44% | +$52.2M |
|
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $163M | 2.07% | +8,909,091 | New | +$163M |
|
12
4D Molecular Therapeutics
FDMT
$288M
| $161M | 2.05% | 5,051,511 +888,300 | +21% | +$28.3M |
|
13
Biogen
BIIB
$19.4B
| $160M | 2.03% | 740,727 +207,835 | +39% | +$44.8M |
|
14
PepGen
PEPG
$38M
| $157M | 2% | 10,689,545 +2,557,593 | +31% | +$37.6M |
|
15
Geron
GERN
$893M
| $152M | 1.94% | 46,202,425 | – | – |
|
16
89bio
ETNB
$1.34B
| $149M | 1.89% | 12,766,948 +1,350,000 | +12% | +$15.7M |
|
|
17
Dyne Therapeutics
DYN
$1.92B
| $141M | 1.79% | +4,954,779 | New | +$141M |
|
18
Apogee Therapeutics
APGE
$2.17B
| $131M | 1.67% | 1,977,901 | – | – |
|
19
Day One Biopharmaceuticals
DAWN
$769M
| $129M | 1.64% | 7,809,852 | – | – |
|
20
Nkarta
NKTX
$151M
| $117M | 1.49% | 10,805,129 +3,000,000 | +38% | +$32.4M |
|
21
Wave Life Sciences
WVE
$1.53B
| $112M | 1.43% | 18,202,009 | – | – |
|
22
ARS Pharmaceuticals
SPRY
$1.15B
| $111M | 1.41% | 10,860,977 +1,401,299 | +15% | +$14.3M |
|
23
Fulcrum Therapeutics
FULC
$351M
| $110M | 1.39% | 11,609,704 | – | – |
|
|
VRNA
24
Verona Pharma
VRNA
$9.16B
| $102M | 1.29% | 6,317,990 | – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $93.3M | 1.19% | +4,178,823 | New | +$93.3M |
|